工業大麻板塊異動拉昇 紫鑫藥業漲停
格隆匯5月26日丨工業大麻板塊異動拉昇,紫鑫藥業漲停,龍津藥業漲超7%,方盛製藥漲超6%,順灝股份、福安藥業等跟漲。工業大麻作為具有巨大應用前景的戰略新興產業,已越來越受到國家及相關部門的重視。在剛召開的全國兩會上,全國政協常委趙雨森就提交了關於促進工業大麻產業發展的提案。提案表示,目前全球工業大麻產品年銷售額超過100億美元,未來5年預計增加到1000億美元以上,有潛力發展成萬億級產業。隨着大麻二酚(CBD)在醫藥保健領域的應用逐漸被市場認可,工業大麻及相關產業具有廣闊的發展空間。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.